Boston Scientific (BSX) AI Stock Analysis

• Market Cap: $154.34B
• Dividend Yield: N/A
• Average Volume (3M): 7.43M
• Price to Earnings (P/E): 76.4
• Beta (1Y): 0.83
• Revenue Growth: 19.35%
• EPS Growth: 14.31%
• Country: US
• Employees: 53,000
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): 0.75
• Shares Outstanding: 1,479,446,300
• 10 Day Avg. Volume: 7,608,821
• 30 Day Avg. Volume: 7,430,294
• PEG Ratio: 7.96
• Price to Book (P/B): 6.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 53.72
• Enterprise Value/Market Cap: 1.07
• Enterprise Value/Revenue: 2.53
• Enterprise Value/Gross Profit: 13.72
• Enterprise Value/Ebitda: 10.78
• 1Y Price Target: $119.57
• Price Target Upside: 14.62% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 22

• Rating: 74 Outperform
• Price Target: $113.00 ▲(8.32%Upside)

Boston Scientific's overall stock score reflects its strong financial performance and positive earnings outlook, which are partially offset by high valuation and mixed technical indicators. The company's strategic initiatives in cardiology and electrophysiology are driving growth, though external challenges like tariffs and regulatory pressures present risks.

Positive Factors

Innovation and Market Position

Boston Scientific is very well-positioned to deliver above-consensus results in its Electrophysiology and Watchman businesses, driven by the highly attractive growth dynamics of these end markets.

Market Leadership

Boston Scientific's Watchman Left Atrial Appendage Closure device holds a 90% share of its market, benefiting from more time before facing competition from JNJ.

Revenue Growth

Analyst maintains a Buy rating on Boston Scientific due to a durable double-digit revenue growth outlook with high margin revenue potential.

Negative Factors

Clinical Trial Delays

The IDE study evaluating the LAMINAR Left Atrial Appendage Elimination device was voluntarily paused due to issues with unwrapping, leading to leaks in select device sizes.

Revenue Impact

The loss of approximately $200 million ACURATE OUS revenue is about a 1-point impact to Boston Scientific's growth rate.

Boston Scientific Business Overview & Revenue Model

Company Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

How the Company Makes Money

Boston Scientific makes money primarily through the sale of its medical devices and technologies across its different business sectors. The company generates revenue from hospitals, clinics, and health systems that purchase its products for use in various medical procedures. Key revenue streams for Boston Scientific include its Cardiovascular segment, which offers products for coronary interventions, structural heart therapies, and peripheral interventions; the Rhythm Management segment, providing devices for cardiac rhythm disorders; and the MedSurg segment, which includes products for endoscopy, urology, and pelvic health. Additionally, Boston Scientific benefits from strategic partnerships and acquisitions that enhance its product portfolio and expand its market presence, contributing to its overall earnings.

Boston Scientific Financial Statement Overview

Summary

Boston Scientific demonstrates strong financial performance with consistent revenue growth, solid profitability, and efficient cash flow management. Notably, the company maintains strong gross and net profit margins and a healthy balance sheet with manageable leverage. However, there is room for improvement in reducing debt levels.

Income Statement

Boston Scientific has demonstrated robust growth in its revenue, with a notable TTM (Trailing-Twelve-Months) increase of 4.81% compared to the previous year. The company maintains strong gross and net profit margins at 67.15% and 11.57% respectively, indicating efficient cost management and profitability. The EBIT and EBITDA margins are solid at 17.52% and 21.65%, reflecting operational efficiency. Overall, the company shows a positive growth trajectory in the medical devices industry.

Balance Sheet

The balance sheet reflects a healthy financial position with a Debt-to-Equity ratio of 0.51, showing manageable leverage. The Return on Equity (ROE) stands at a strong 9.15%, indicating effective utilization of shareholders' equity. The Equity Ratio is 55.33%, suggesting a stable asset base supported by equity. Overall, the company maintains a strong balance between debt and equity, although there is room for improvement in reducing debt levels.

Cash Flow

Boston Scientific exhibits strong cash flow management with a Free Cash Flow growth rate of 8.62%, indicating improved cash generation. The Operating Cash Flow to Net Income ratio is 1.88, demonstrating the company's ability to convert income into cash efficiently. The Free Cash Flow to Net Income ratio is 1.41, reflecting good cash flow productivity. Overall, the company shows robust cash flow health, supporting its financial stability and operational needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.55B	16.75B	14.24B	12.68B	11.89B	9.91B
Gross Profit	12.05B	11.49B	9.89B	8.68B	8.13B	6.40B
EBITDA	4.09B	3.86B	3.45B	2.74B	2.52B	1.51B
Net Income	2.03B	1.85B	1.59B	698.00M	1.04B	-140.00M
Balance Sheet
Total Assets	40.14B	39.40B	35.14B	32.47B	32.23B	30.78B
Cash, Cash Equivalents and Short-Term Investments	725.00M	414.00M	865.00M	928.00M	1.93B	1.73B
Total Debt	11.71B	11.15B	9.49B	9.28B	9.45B	9.54B
Total Liabilities	17.69B	17.39B	15.61B	14.90B	15.61B	15.45B
Stockholders Equity	22.21B	21.77B	19.28B	17.57B	16.62B	15.33B
Cash Flow
Free Cash Flow	2.87B	2.65B	1.70B	914.00M	1.32B	1.13B
Operating Cash Flow	3.81B	3.44B	2.50B	1.53B	1.87B	1.51B
Investing Cash Flow	-5.90B	-5.69B	-2.57B	-2.01B	-1.60B	-411.00M
Financing Cash Flow	2.15B	1.81B	5.00M	-548.00M	-95.00M	293.00M

Boston Scientific Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 104.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSX, the sentiment is Positive. The current price of 104.32 is above the 20-day moving average (MA) of 102.50, above the 50-day MA of 103.27, and above the 200-day MA of 95.90, indicating a bullish trend. The MACD of 0.69 indicates Negative momentum. The RSI at 54.03 is Neutral, neither overbought nor oversold. The STOCH value of 50.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BSX.

Boston Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SYK	81 Outperform	$151.06B	53.34	14.26%	0.85%	10.76%	-15.22%
DXCM	78 Outperform	$32.52B	62.26	23.72%	―	9.11%	-17.87%
MDT	77 Outperform	$113.25B	24.46	9.49%	3.21%	3.62%	31.18%
BSX	74 Outperform	$154.34B	76.44	9.65%	―	19.35%	14.31%
ABT	74 Outperform	$233.90B	17.44	30.66%	1.75%	5.00%	139.98%
ABT	74 Outperform	$233.90B	17.44	30.66%	1.75%	5.00%	139.98%
EW	64 Neutral	$45.05B	51.31	16.73%	―	-9.84%	-35.77%
Sector *	52 Neutral	$7.53B	0.32	-61.76%	2.28%	16.60%	1.56%

Boston Scientific Corporate Events

Boston Scientific Discontinues Aortic Valve Systems

On May 28, 2025, Boston Scientific announced the discontinuation of its ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems, ceasing global sales and halting pursuit of FDA approval due to increased regulatory demands. Despite the financial implications, the company expects to meet its sales and earnings guidance for 2025, though it is withholding reaffirmation of its GAAP EPS guidance until further updates in its second quarter earnings call.

The most recent analyst rating on (BSX) stock is a Buy with a $113.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.

Boston Scientific Stockholders Approve Key Governance Proposals

On May 1, 2025, Boston Scientific held its Annual Meeting of Stockholders virtually, where all 10 director nominees were elected for a one-year term. Additionally, stockholders approved the compensation for the company’s Named Executive Officers, ratified the appointment of Ernst & Young LLP as the independent public accounting firm for 2025, and supported a proposal for a simple majority vote, indicating strong shareholder engagement and support for the company’s governance and strategic direction.

Boston Scientific Announces CFO Retirement and Successor

On April 23, 2025, Boston Scientific announced the retirement of Dan Brennan, its Chief Financial Officer, after nearly 30 years with the company. Brennan will be succeeded by Jon Monson, currently the Senior Vice President of Investor Relations, effective June 30, 2025. Monson, with over 25 years at Boston Scientific, brings extensive financial expertise and will oversee several key company functions. This leadership transition is expected to ensure continuity and further strengthen the company’s financial strategies and operations.